GlaxoSmithKline Pharmaceuticals Q1 FY27 earnings call

GlaxoSmithKline Pharmaceuticals Limited reported a strong Q1 FY27 with sales growing 15% year-on-year to INR 924 crores. EBITDA increased by 17%, outpacing sales growth, and EBITDA margins improved by 50 basis points. Profit after tax (PAT) saw a 24% rise to INR 253 crores, with PAT margins reaching 27.6%, though this included a one-off^📎 dividend from a subsidiary that, if excluded, would result in 17% PAT growth.

The company's global strategy focuses on strengthening its position as a biopharmaceutical major, with three key priorities: relentless top-line growth, accelerating pipeline launches, and operational simplification. The Indian pharmaceutical industry grew by approximately 13.5% in Q1, with balanced growth across volume, price, and new introductions. GSK's portfolio, while skewed towards acute segments, benefited from balanced growth in both acute and chronic areas.

The innovation portfolio, comprising IP-protected assets like Zejula for ovarian cancer and Jemperli for endometrial cancer, contributed significantly, accounting for 7-7.5% of total revenues this quarter. These products, which did not exist three years ago, have impacted over 260-270 patients. Nucala, an innovative asset for severe eosinophilic asthma, saw its new patient uptake double to 100-120 patients monthly.

The General Medicines business, which remains a significant portion of revenue, grew well in double digits, with all brands outperforming the market according to IQVIA. The vaccines business maintained market leadership in the private segment, with Shingrix delivering 65% growth for the quarter and selling 45,000-50,000 doses quarterly, crossing the INR 100 crore mark on a MAT basis. Trelegy Ellipta also continued to grow despite generic launches.

The company made significant investments in Q1, particularly in oncology and adult vaccination, leading to a temporary increase in the spend-to-sales ratio by about a percentage point. Management expects these investment ratios to moderate in subsequent quarters, with S&A ratios normalizing and EBITDA margins returning to the 34% range seen last year. Gross margins improved by 150 bps despite some hardening of costs from rupee depreciation, indicating effective cost management.

GSK is preparing for the launch of several innovative assets, including Blenrep for multiple myeloma (expected in 2-3 months) and Bepirovirsen for Hepatitis B (expected within three quarters). The company aims for INR 8,000 crores in top-line revenue within 4-5 years, implying a 13-14% CAGR. This growth is expected to be driven by these high-growth, high-value segments while maintaining current levels of profitability.